Show summary Hide summary
Johnson & Johnson’s chief executive told the WSJ Leadership Institute CEO Summit in London that recent advances in immunotherapy are changing the outlook for certain cancers — and could make cures realistic for some patients within the next decade. His remarks focused on dramatic improvements in survival for blood cancers such as multiple myeloma and on how new tools, including AI and precision drugs, are reshaping research priorities today.
Speaking at the summit, Joaquin Duato said the company is concentrating on therapies that harness the patient’s own immune system to attack tumors, producing outcomes that were unimaginable a few years ago. He highlighted cases in which single-dose treatments have delivered extended remissions for patients who previously had exhausted standard options.
From months to years: a shift in outcomes
Supreme Court curbs mass Roundup claims: thousands of suits paused nationwide
MLB All-Star fan voting shocks: surprise leaders and snubs that change rosters
Duato pointed to multiple myeloma as a clear example of progress. Where life expectancy once measured only in a few years, he said, median survival in many settings now approaches a decade — a gain driven largely by targeted agents and immune-based approaches.
He described patients who were approaching end-of-life care but, after receiving novel immunotherapies, have remained disease-free for more than five years following a single administration. Those kinds of durable responses, he argued, are changing expectations for clinicians and patients alike.
What J&J is prioritizing
According to Duato, the company is advancing a two-track strategy: deepen scientific understanding of cancer biology and develop technologies that can translate that knowledge into therapies. That work spans cell- and gene-based immunotherapies as well as small molecules designed to penetrate cells and act on previously “undruggable” mutations.
Earlier this year J&J acquired Firefly Bio, a biotech firm focused on drugs that enter cancer cells to target proteins produced by hard-to-treat gene mutations — a move Duato presented as part of the broader effort to expand the company’s oncology toolbox.
AI, diagnostics and broader health stakes
Duato also highlighted the growing role of artificial intelligence in drug discovery and patient care, calling it a “force multiplier” for research teams. He suggested that AI-driven biomarkers and imaging could enable earlier detection and more personalized surgical and medical decisions.
Beyond cancer, Duato named dementia as another major area of unmet need and said advances that extend healthy lifespan will continue to reshape healthcare priorities. He predicted that, as longevity technologies progress, average life expectancy and quality of life will rise together.
- Clinical implications: Durable remissions from immunotherapies could reduce reliance on repetitive, incremental treatments and change care pathways for some patients.
- Research focus: Targeting intracellular proteins and hard-to-drug mutations is a rising priority for large pharma and biotechs alike.
- Technology role: AI and biomarker platforms are expected to speed diagnosis, trial selection and personalized treatment planning.
- Public health impact: Improvements in survival for specific cancers may shift them toward chronic-disease management for many patients.
While Duato framed these developments as realistic steps toward curing certain cancers and converting others into manageable conditions, the pace of progress will depend on successful clinical trials, regulatory approvals and broader access to new therapies. Still, the combination of immune-based treatments, precision drugs and digital tools is already altering clinical expectations and could meaningfully change patient outcomes in the near term.
